CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Bio-Techne delivered Q3 FY 26 (Jun.) adjusted EPS of $0.53, in-line with consensus, while sales declined 2% to $311.4M amid challenging conditions and unfavorable Commercial Supply timing. Double-digit pharma growth for the sixth consecutive quarter helped offset the gradually recovering biotech funding environment. We believe the company's diversified portfolio and strong financial flexibility position Bio-Techne to capitalize on improving market conditions. Management expressed cautious optimism about improving end-market fundamentals, noting early indicators of better alignment between biotech funding and customer purchasing. U.S. academic markets showed stabilization with low-single-digit growth, representing improvement from recent weakness. Protein Sciences revenue declined 1% to $226.2M with 44.2% operating margin, while Diagnostics and Spatial Biology revenue fell 4% to $85.6M but operating margin improved to 12.1% following the Exosome divestiture.